Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
3 papers
Recent·Most cited
R. H. Shoemaker, R. A. Panettieri, S. K. Libutti…·G. Wirnsberger
This paper reports preclinical development and evaluation of aerosolized soluble recombinant human ACE2 (APN01) as a COVID-19 intervention.
T. Capraz, N. F. Kienzl, E. Laurent…·J. Stadlmann
This study engineers ACE2 glycosylation to enhance its binding to SARS-CoV-2 Spike protein, resulting in a more potent decoy receptor for COVID-19 treatment.
R. Gawish, P. Starkl, L. Pimenov…·S. Knapp
This paper develops a mouse-adapted SARS-CoV-2 strain, maVie16, to model COVID-19 in mice, showing that ACE2 is critical for disease and that blocking TNF/IFNγ reduces immunopathology.